Diversity Council Business Blog

Trending

Akeso’s AK157D1 (B7-H3 ADC) Cleared for Phase I Trial in Solid Tumors, Adding a Third Differentiated ADC to Its Pipeline

HONG KONG, Aug. 21, 2026 /PRNewswire/ — Akeso, Inc. (9926.HK) (“Akeso” or the “Company”) today announced that its investigational next-generation B7-H3-targeting antibody-drug conjugate (ADC), AK157D1, has received clinical trial clearance from the Center for Drug Evaluation (CDE) of…

Akeso’s AK157D1 (B7-H3 ADC) Cleared for Phase I Trial in Solid Tumors, Adding a Third Differentiated ADC to Its Pipeline Read More »

Akiram Therapeutics and ITM Sign Lutetium-177 Supply Agreement to Support Development of AKIR001 for the Treatment of Solid Tumors

Akiram Therapeutics, a Swedish clinical-stage biotech company specializing in molecular radiotherapy, and ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced a supply agreement for non-carrier-added (n.c.a.) Lutetium-177 (Lu-177 or 177Lu) to support the…

Akiram Therapeutics and ITM Sign Lutetium-177 Supply Agreement to Support Development of AKIR001 for the Treatment of Solid Tumors Read More »

Hansa Biopharma announces first commercial kidney transplant patient treated with Idefirix in Australia

LUND, Sweden, Aug. 18, 2026 /PRNewswire/ — Hansa Biopharma AB, “Hansa” (Nasdaq Stockholm: HNSA), today announced that the first commercial patient in Australia has received a living donor kidney transplant following treatment with Idefirix® (imlifidase), consistent with the…

Hansa Biopharma announces first commercial kidney transplant patient treated with Idefirix in Australia Read More »

MindMaze Therapeutics Completes Organizational Simplification and Provides Update on Neuro.io Equity Financing

GENEVA, Aug. 10, 2026 /PRNewswire/ — MindMaze Therapeutics Holding SA (SIX: MMTX) (MindMaze Therapeutics or the Company), a global leader in scalable precision neurotherapeutics, today provided updates on two previously announced initiatives supporting its strategic priorities in neurology:…

MindMaze Therapeutics Completes Organizational Simplification and Provides Update on Neuro.io Equity Financing Read More »

Innogen Pharmaceuticals Receives PIC/S GMP Certificatation, Accelerating Global Expansion of Efsubaglutide Alfa

SHANGHAI, Aug. 4, 2026 /PRNewswire/ — Innogen Pharmaceuticals (HK.2591), a biopharmaceutical company dedicated to innovative drug discovery and industrialization in metabolic diseases, today announced that its Efsubaglutide alfa manufacturing facility in Suzhou has officially passed a compliance inspection…

Innogen Pharmaceuticals Receives PIC/S GMP Certificatation, Accelerating Global Expansion of Efsubaglutide Alfa Read More »

U.S. News & World Report Ranks MedStar Health Hospitals #1 in the D.C. Region for Cancer, Cardiology, Heart & Vascular Surgery, and Rehabilitation

COLUMBIA, Md., Aug. 4, 2026 /PRNewswire/ — MedStar Health is celebrating high praise for its hospitals in U.S. News & World Report’s Best Hospitals rankings for 2026-27, including prestigious national and regional recognition for exceptional patient care. Each year,…

U.S. News & World Report Ranks MedStar Health Hospitals #1 in the D.C. Region for Cancer, Cardiology, Heart & Vascular Surgery, and Rehabilitation Read More »